WEKO3
アイテム
{"_buckets": {"deposit": "517c3ae0-c925-4d56-83a9-c8915c0a2afb"}, "_deposit": {"created_by": 1, "id": "46409", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "46409"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00046409", "sets": ["1"]}, "author_link": ["462306", "462302", "462301", "462305", "462304", "462300", "462307", "462303"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "2360", "bibliographicPageStart": "2351", "bibliographicVolumeNumber": "31", "bibliographic_titles": [{"bibliographic_title": "Anticancer Research"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "AIM: We investigated whether hypoxia-inducible factor-1aphpa (HIF-1aphpa) expression in pretreatment biopsies of esophageal cancer is predictive of clinical outcome in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). PATIENTS AND METHODS: A total of 25 patients were reviewed. Radiotherapy was administered to total doses of 40-66.6 Gy (median: 66.6 Gy) with a single fraction of 1.8-2 Gy. Cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 2-6) were administered concurrently with radiotherapy, every 3-4 weeks to a total of 1-2 courses. Tissue samples from esophageal cancer were obtained from all 25 patients by biopsy before concurrent CRT, and semiquantitative analyses of HIF-1aphpa expression were performed using immunohistochemical staining. RESULTS:High HIF-1aphpa expression was observed in 11 out of 25 patients (42.7%), and HIF-1aphpa expression was significantly correlated with initial response to CRT (p=0.0027). Patients with high HIF-1aphpa expression had significantly poorer local control (LC) (5-year LC: 42.7%) than those with low expression (5-year LC: 72.5%; p=0.0322). Patients with high HIF-1aphpa expression also had significantly lower recurrence-free survival (RFS) (5-year RFS: 18.2%) compared to those with low HIF-1aphpa expression (5-year RFS: 39.8%; p=0.0009), and on multivariate analysis, HIF-1aphpa (p=0.001) and number of chemotherapy courses (p=0.010) were independent prognostic factors for RFS. CONCLUSION: HIF-1aphpa expression is significantly correlated with initial response to concurrent CRT, and is predictive of RFS for patients with esophageal cancer receiving concurrent CRT.", "subitem_description_type": "Abstract"}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0250-7005", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ogawa, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "462300", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Chiba, Itaru"}], "nameIdentifiers": [{"nameIdentifier": "462301", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morioka, Takamitsu"}], "nameIdentifiers": [{"nameIdentifier": "462302", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshimi, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "462303", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murayama, Sadayuki"}], "nameIdentifiers": [{"nameIdentifier": "462304", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "et.al"}], "nameIdentifiers": [{"nameIdentifier": "462305", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "森岡 孝満", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "462306", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉見 直己", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "462307", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy."}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/46409", "pubdate": {"attribute_name": "公開日", "attribute_value": "2012-10-02"}, "publish_date": "2012-10-02", "publish_status": "0", "recid": "46409", "relation": {}, "relation_version_is_last": true, "title": ["Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy."], "weko_shared_id": -1}
Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.
https://repo.qst.go.jp/records/46409
https://repo.qst.go.jp/records/46409aeb73942-80bd-4ca7-a3e4-96ee0218f1d0
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-10-02 | |||||
タイトル | ||||||
タイトル | Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Ogawa, Kazuhiko
× Ogawa, Kazuhiko× Chiba, Itaru× Morioka, Takamitsu× Yoshimi, Naoki× Murayama, Sadayuki× et.al× 森岡 孝満× 吉見 直己 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | AIM: We investigated whether hypoxia-inducible factor-1aphpa (HIF-1aphpa) expression in pretreatment biopsies of esophageal cancer is predictive of clinical outcome in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). PATIENTS AND METHODS: A total of 25 patients were reviewed. Radiotherapy was administered to total doses of 40-66.6 Gy (median: 66.6 Gy) with a single fraction of 1.8-2 Gy. Cisplatin (80 mg/m2 on day 1) and 5-fluorouracil (800 mg/m2 on days 2-6) were administered concurrently with radiotherapy, every 3-4 weeks to a total of 1-2 courses. Tissue samples from esophageal cancer were obtained from all 25 patients by biopsy before concurrent CRT, and semiquantitative analyses of HIF-1aphpa expression were performed using immunohistochemical staining. RESULTS:High HIF-1aphpa expression was observed in 11 out of 25 patients (42.7%), and HIF-1aphpa expression was significantly correlated with initial response to CRT (p=0.0027). Patients with high HIF-1aphpa expression had significantly poorer local control (LC) (5-year LC: 42.7%) than those with low expression (5-year LC: 72.5%; p=0.0322). Patients with high HIF-1aphpa expression also had significantly lower recurrence-free survival (RFS) (5-year RFS: 18.2%) compared to those with low HIF-1aphpa expression (5-year RFS: 39.8%; p=0.0009), and on multivariate analysis, HIF-1aphpa (p=0.001) and number of chemotherapy courses (p=0.010) were independent prognostic factors for RFS. CONCLUSION: HIF-1aphpa expression is significantly correlated with initial response to concurrent CRT, and is predictive of RFS for patients with esophageal cancer receiving concurrent CRT. | |||||
書誌情報 |
Anticancer Research 巻 31, 号 6, p. 2351-2360, 発行日 2011-06 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0250-7005 |